NCT03864432View on ClinicalTrials.gov

An Ascending Dose, Single/Multiple Dosing, Food Effect Clinical Trial to Evaluate Pharmacokinetics, Safety and Tolerability in Healthy Subjects After Oral Administration of Gemigliptin (Phase I)

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

July 2, 2019

Primary Completion Date

October 3, 2019

Study Completion Date

February 28, 2020

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

Gemigliptin 25mg

Gemigliptin 50mg 1/2T

DRUG

Gemigliptin 50mg

Gemigliptin 50mg 1T

DRUG

Gemigliptin 100mg

Gemigliptin 50mg 2T

DRUG

Gemiglptin 50mg multiple dose

Gemigliptin 50mg 1T \* 10days

Trial Locations (1)

200002

Shanghai Xuhui Central hospital, Shanghai

Sponsors

Lead Sponsor

LG Chem
All Listed Sponsors
lead

LG Chem

INDUSTRY

NCT03864432 - An Ascending Dose, Single/Multiple Dosing, Food Effect Clinical Trial to Evaluate Pharmacokinetics, Safety and Tolerability in Healthy Subjects After Oral Administration of Gemigliptin (Phase I) | Biotech Hunter | Biotech Hunter